Biogen Inc

The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in development by other companies.

Shares of Biogen Inc fell nearly 10% on Wednesday after the U.S. government announced limited coverage of Alzheimer's treatments including the drugmaker's Aduhelm, dealing a blow to the controversial treatment that was approved last year.

* BIOGEN - TO CONTINUE TO URGE CMS TO ALIGN MEDICARE COVERAGE FOR CLASS OF AMYLOID-DIRECTED THERAPIES WITH POPULATIONS STUDIED IN RESPECTIVE CLINICAL TRIALS, FOR APPROPRIATE USE

The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected.

The U.S. government's Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm, with some conditions.

The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week from the U.S. Medicare program on whether it will pay for the treatment.

U.S. Secretary of Health and Human Services Xavier Becerra on Monday asked the country's Medicare program to reassess its 2022 premium hikes, weeks after Biogen Inc cut the price of its Alzheimer's drug by about half.

Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.

Samsung BioLogics said in a regulatory filing on Thursday that a report saying Samsung Group is in talks to acquire U.S. drugmaker Biogen Inc is not true.

South Korea's Samsung Group is in talks to buy drugmaker Biogen Inc, the Korea Economic Daily reported https://www.kedglobal.com/newsView/ked202112290011?lang=us on Wednesday, citing investment banking sources.

Biogen Inc and Japanese partner Eisai Co said on Thursday the U.S. Food and Drug Administration (FDA) had granted "fast track" designation to their experimental therapy lecanemab for the treatment of early Alzheimer's disease.

A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.

Biogen Inc on Monday cut the price of its Alzheimer's drug by about half to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits.

Biogen Inc said on Monday it would reduce the price of its Alzheimer's disease drug by about 50%, representing a yearly cost of $28,200 per patient. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)

The European Union's drug regulator on Friday rejected Biogen Inc's controversial Alzheimer's drug, Aduhelm, dealing a blow to the U.S. drugmaker after a panel voted against the treatment last month.

The European Union's drug regulator said on Friday it had recommended against approving Biogen Inc's Alzheimer's drug, Aduhelm, dealing a blow to the U.S. drugmaker after a panel voted against the treatment last month.

Biogen Inc said on Thursday it was expecting to submit a final design for a post-marketing confirmatory study of its newly approved Alzheimer's drug, Aduhelm, to the U.S. Food and Drug Administration in March, and begin screening of patients in May.

A European Medicines Agency panel voted against approval of Biogen Inc's Alzheimer's drug Aduhelm, in another blow to prospects for a treatment already grappling with a slow rollout in the United States.

Biogen Inc said on Wednesday the European Medicines Agency's panel had given a negative trend vote against the marketing application for its Alzheimer's disease drug. (Reporting by Manas Mishra in Bengaluru; Editing by Krishna Chandra Eluri)